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As of June 2008, there were 285 re-
ported cases of avian influenza, of which 
243 were fatal. Jeremy Farrar has been 
involved with most of the 35 cases re-
ported in Vietnam. In addition to treat-
ing patients, he is part of a collaborative 
effort to prevent this devastating virus 
from reaching epidemic proportions.
Farrar’s early work focused on infec-
tions of the brain (1). But like many clin-
ical scientists in Southeast Asia, Farrar 
now works on a number of indigenous 
afflictions, including malaria, typhoid, 
dengue fever, and other emerging infec-
tious diseases (2). In the last few years, Far-
rar has focused on the pathophysiology 
and treatment of avian influenza (3, 4). He 
is also exploring the cross-reactivity of 
memory T cell responses to influenza in 
hopes of creating a broadly protective 
vaccine for H5N1 (5).
THE CALL
Do you remember what you were doing 
when you fi  rst heard that the bird fl  u had 
hit Ho Chi Minh City?
Yes, I remember vividly. It was a mo-
ment I’d been dreading. It was late at 
night during the Vietnamese New Year 
in January 2004.
I got a phone call from a friend who 
was a doctor in the hospital. There had 
been a group from the 
WHO visiting Ho Chi 
Minh City. They’d been in 
Hanoi, where the first case 
had been diagnosed a few 
days before. We had only 
just come through SARS 
and when the first case of 
influenza appeared, there 
was a huge fear that these 
new, unusual respiratory infections were 
a reoccurrence of SARS.
What happened?
The WHO team was visiting hospitals 
advising people to be watchful of unu-
sual respiratory illnesses. During their 
visit, the team and my colleague, Pro-
fessor [Tran Tinh] Hien, who’s the vice 
director at the Hospital for Tropical 
Diseases, went to see a child that the 
doctors were a little bit worried about. 
The WHO people—and this is not a 
criticism—decided it was unlikely that 
the child had SARS or avian infl  uenza. 
They left, but Professor Hien stayed be-
hind to talk with the child and her 
mum. The girl admitted that she had 
been quite sad in the previous days with 
the death of her pet duck. The girl and 
her brother had fought over burying 
the duck and, because of this argument, 
she had gone back, dug up the duck, 
and reburied it—probably so her broth-
er wouldn’t know where it was buried.
With that history, Professor Hien 
phoned me at home and said he was 
worried about the child. He took some 
swabs from the child’s nose and throat 
and brought them back to the hospital. 
That night the laboratory ran tests on 
the samples, and they were positive for 
Influenza A. So we started treatment 
sometime after midnight, and the child 
survived. It’s actually a lovely story be-
cause it shows you that in clinical 
medicine, taking a good history and 
being able to act quickly is still very 
important. As a result, the girl survived 
and is now a very happy teenager back 
in school.
This must have been terrifying if you’ve 
remembered it so well.
It was. This was a year or two after 
SARS. Everybody across Asia was fright-
ened of this disease reappearing, and it 
was particularly frightening for medical 
staff   because SARS had been so infec-
tious between people. In fact a good 
friend of mine, Carlo Urbani, who was 
the WHO representative in Hanoi, died 
of SARS as a result of identifying patients 
and then ensuring that the hospital was 
closed off  . He stayed in the hospital for 
two or three weeks and didn’t leave. His 
actions probably prevented SARS from 
breaking out across Vietnam. It was an 
incredibly courageous thing to do.
And of course, when you have an 
unusual respiratory infection in a hospi-
tal—whether it’s in Ho Chi Minh City 
or Jakarta or Beijing or London or 
Washington, DC—and you have no 
idea what it is, it creates a frightening 
environment. You’re first a human be-
ing and second a doctor, and yes, it was 
frightening. That’s why it’s so etched in 
our minds, I think.
Do you still worry when you hear about 
new cases of avian infl  uenza?
Now, in 2008, I’m less worried than I was 
in 2004. In retrospect you can say, “Per-
haps we didn’t need to be so worried.” 
But at the time we didn’t know that.
Now there is some consensus that H5N1 
won’t pass between humans. Is the attention 
it continues to receive from both the public 
and granting agencies exaggerated?
No, I think the world has been right to 
take this seriously. The chance of some-
thing terrible happening is small, but it’s 
also not quantifi   able. I can’t tell you 
whether it’s 1% or 5% or 0.001%. How-
ever if [human-to-human transmission] 
were to happen, it would be a cata-
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strophic event. One that’s very diffi   cult 
to cope with.
Also, some of the investment that 
has come about as a result of the out-
breaks has been very well spent. The 
capacity for diagnosis, treatment, and 
disease surveillance has improved im-
measurably in the past four years. It 
went from being nonexistent in many 
places across Asia to being infinitely bet-
ter than it was.
SEARCHING FOR A QUICK FIX
When a patient comes in with avian 
infl  uenza, is it clearly something diff  erent 
than a normal fl  u?
It’s variable. For a few days there’s 
coughing and a fever, gradually it gets 
worse, and by the time these patients 
seek medical attention, they are often 
extremely sick. And not just with an 
infection of the lungs like in normal 
human fl  u. We saw one patient, for in-
stance, who seemed to have a brain in-
fection. And others had an infection of 
the liver or the kidneys. The patients 
can get worse very quickly. That’s why 
the mortality rate has been so high. 
Sixty percent of reported cases have re-
sulted in death.
Have treatments for infl  uenza improved 
since the fi  rst outbreak of H5N1?
Over the last 30 years infl  uenza has to a 
degree been neglected. We have a single 
drug, oseltamivir [a neuraminidase in-
hibitor], which is widely available. But 
we currently have no drug that we can 
deliver intravenously. To have a single 
drug for an infection caused by an RNA 
virus is a huge risk. Resistance develops 
very quickly in RNA viruses, and com-
bination therapies are needed to treat 
patients. I hope researchers will continue 
to work for better diagnostics, better 
drugs, and a better vaccine. It’s an insur-
ance policy against the tiny risk of a very 
major problem.
Thus far, antibody-based vaccines against 
avian infl  uenza have had limited success. 
Do you think we know enough about the 
T cell response to infl  uenza to develop a 
T cell–based vaccine in the near future?
No, I don’t think we do. Understanding 
what mediates protection against RNA 
viruses like HIV or infl  uenza, whether it 
is antibody–mediated, T cell–mediated, 
or both, has proven elusive.
In the end, my belief is that it’s prob-
ably a false division. You may like to 
push the T cell response or the antibody 
response but, ultimately, for long-term 
protection, you’re going to need both 
for a vaccine to be functional. In the 
case of the influenza vaccine, we are still 
dependent on a technology that was de-
veloped 40 or 50 years ago.
But that is changing. Many organi-
zations are now investing in research 
to make better influenza vaccines that 
could be produced more quickly in re-
sponse to threats. The world really 
does need more than a single drug and 
a system of making flu vaccines more 
quickly and effectively than we’ve 
done in the past. You could be a real 
optimist—as long you weren’t one of 
those people who caught H5N1—and 
say that this has been a sort of wake-up 
call to the potential consequences of 
an influenza pandemic.
A SUSTAINABLE SOLUTION
A good portion of your research is done at 
the laboratory bench, so why in Vietnam?
In my view, I think a more equitable way 
of approaching international health is to 
move the center of gravity from the de-
veloped world and bring the research to 
the countries that are most aff  ected  by 
those illnesses, to allow the 
benefi  ts of that research to 
be felt by the people in 
those countries. And there 
needs to be a critical mass 
of people dedicated to re-
search. No matter how bril-
liant you are, you’re totally 
dependent on your col-
leagues around you. One 
person can’t make a diff  er-
ence. I think there’s been a 
realization that [infectious 
disease research] has to shift to where the 
diseases are. And it’s happening, but it 
needs to speed up, particularly in parts of 
Africa, Asia, and Latin America as econo-
mies develop and enlightened funding 
agencies see the need to make that shift.
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“Understanding 
what mediates 
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against RNA 
viruses like HIV 
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